Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

SPX Technologies (SPXC) Other Operating Expenses (2016 - 2025)

SPX Technologies has reported Other Operating Expenses over the past 13 years, most recently at -$500000.0 for Q2 2025.

  • Quarterly results put Other Operating Expenses at -$500000.0 for Q2 2025, up 94.05% from a year ago — trailing twelve months through Dec 2025 was -$96.0 million (up 1.44% YoY), and the annual figure for FY2025 was -$500000.0, up 94.05%.
  • Other Operating Expenses for Q2 2025 was -$500000.0 at SPX Technologies, up from -$95.5 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for SPXC hit a ceiling of $24.3 million in Q4 2021 and a floor of -$95.5 million in Q1 2025.
  • Median Other Operating Expenses over the past 5 years was -$8.4 million (2024), compared with a mean of -$24.8 million.
  • Biggest five-year swings in Other Operating Expenses: plummeted 322.29% in 2022 and later surged 94.05% in 2025.
  • SPX Technologies' Other Operating Expenses stood at -$17.5 million in 2021, then crashed by 322.29% to -$73.9 million in 2022, then skyrocketed by 87.82% to -$9.0 million in 2023, then grew by 6.67% to -$8.4 million in 2024, then surged by 94.05% to -$500000.0 in 2025.
  • The last three reported values for Other Operating Expenses were -$500000.0 (Q2 2025), -$95.5 million (Q1 2025), and -$8.4 million (Q2 2024) per Business Quant data.